Answers are grounded in this paper and cite their sources.
Many birth abnormalities were widespread fifty years ago as a result of the sedative thalidomide being prescribed.Both leprosy and multiple myeloma are currently treated with the medication.Its use is limited because of its significant teratogenic characteristics.Long-standing mystery is the method by which thalidomide results in deformities of the limbs and other developmental abnormalities.Thalidomide's molecular mechanism of action is explained by a number of theories.We provide an overview of the biology of thalidomide in this review, with a particular emphasis on the molecular pathways underlying its teratogenic effects.We also talk about the unanswered questions.As an orphan drug with anti-inflammatory characteristics, thalidomide is being used off-label for diseases that do not respond to traditional medications.Although thalidomide has been shown to have immunomodulatory effects in clinical trials, the exact way it does this is still not known.This review aims to enhance our comprehension of the potential processes by which thalidomide may be used at the bedside to treat a range of disorders by reviewing both positive and negative bench research.The effects of thalidomide on cancer development, blood vessel formation, and the innate and adaptive immune systems have been the subject of much study.There have been recent discoveries that suggest multiple CRBN neosubstrates, such as p63 (tumor protein P63) and SALL4 (spalt like transcription factor 4), may play a role in the teratogenic effects of thalidomide.With an emphasis on its teratogenicity, we examine what is currently known about the molecular mechanisms of thalidomide.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: